Table 4.
– Survival in hematological patients with COVID-19.
| Survival parameters | N (%) | P value |
|---|---|---|
| N = 130 | ||
| 14-day death rate | 19 (14.6) | |
| 28-day death rate | 26 (20) | |
| 14-day mortality | ||
| Remission (CR/PR) (n = 38) | 3 (7.9) | 0.18 |
| Not in remission (SD/ R/R / not assessed) (n = 92) | 16(17.4) | |
| Mild (n = 68) | 2(2.9) | 0.000 |
| Moderate (n = 28) | 1(3.6) | |
| Severe (n = 34) | 16(47.1) | |
| Age < 60 Years (n = 83) | 7(8.4) | 0.009 |
| Age ≥ 60 Years (n = 47) | 12(25.5) | |
| Active treatment (n = 95) | 15(15.8) | 0.63 |
| Not on active treatment (n = 35) | 4(11.4) | |
| Comorbidities present (n = 54) | 9(16.6) | 0.61 |
| Comorbidities absent (n = 76) | 10(13.2) | |
| 28-day mortality | ||
| Remission (CR/PR) (n = 38)a | 3(7.9) | 0.04 |
| Not in remission (SD/ R/R / not assessed) (n = 92) | 23(25) | |
| Mild (n = 68) | 3(4.4) | 0.00 |
| Moderate (n = 28) | 2(7.1) | |
| Severe (n = 34) | 21(61.7) | |
| Age < 60 Years (n = 83) | 12(14.5) | 0.05 |
| Age > 60 Years (n = 47) | 14(29.8) | |
| Active treatment (n = 95) | 20(21.1) | 0.63 |
| Not on active treatment (n = 35) | 6(17.1) | |
| Comorbidities present (n = 54) | 11(20.4) | 1.0 |
| Comorbidities absent (n = 76) | 15(19.7) | |
a
CR-complete remission, PR-partial remission, SD-stable disease, R/R-relapse refractory